Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC.RCKT · Entity 5627 | See Remarks | May 20, 2025 | May 22, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ROCKET PHARMACEUTICALS, INC.
Report date May 20, 2025 · Filed May 22, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 441,927 |
Reported balance
After 2025-05-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-05-20 · Sale · Disposed 767 · Balance 441,927 F1: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 26,774 |
Reported balance
Holding disclosure · report date 2025-05-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 26,774 |
| Common StockSEC Table I · non-derivative | IndirectBy Adaptive Technology LLC | 104,927 |
Reported balance
Holding disclosure · report date 2025-05-20 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 104,927 F3: The shares are held indirectly through Adaptive Technology, LLC, a limited liability company that is owned and managed by the reporting person's husband. |
Filing footnotes · ownership attribution and instrument terms
F1: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
F2: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.
F3: The shares are held indirectly through Adaptive Technology, LLC, a limited liability company that is owned and managed by the reporting person's husband.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2025 Filed May 22, 2025 20:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 767 | $6.45 | $4,944.08 |
DisclosureSEC source: 0001140361-25-020161 · form4.xml · nonDerivative · entry 1 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 441,927 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| May 16, 2025 Filed May 20, 2025 20:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 1,409 | $6.53 | $9,197.95 |
DisclosureSEC source: 0001140361-25-019901 · form4.xml · nonDerivative · entry 1 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 442,694 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| April 09, 2025 Filed Apr 10, 2025 20:07 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | PurchaseCommon Stock | 21,099 | $4.70 | $99,165.30 |
DisclosureSEC source: 0001140361-25-013253 · form4.xml · nonDerivative · entry 1 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 26,774 F1 · price: On April 9, 2025, the Reporting Person's husband purchased 21,099 shares of Common Stock in a series of brokered transactions at prices ranging from $4.65 to $4.78 and a weighted average price per share of $4.70 (rounded to two decimal places), for an aggregate purchase price of approximately $99,157. The detailed breakdown of executed sales will be furnished upon request. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 21:01 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 6,078 | $10.58 | $64,305.24 |
DisclosureSEC source: 0001140361-25-005847 · form4.xml · nonDerivative · entry 1 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 444,103 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 21:01 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 172,214 | $0.00 Strike: $9.88 | $0.00 |
DisclosureSEC source: 0001140361-25-004294 · form4.xml · derivative · entry 4 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,214 Underlying: Common Stock · 172,214 shares Expires 2035-02-11 F3 · derivative.exercise_date: This option represents a right to purchase a total of 172,214 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 11, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 21:01 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantCommon Stock | 57,786 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-004294 · form4.xml · nonDerivative · entry 1 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,181 F1 · security: Represent RSUs that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on February 11, 2026, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 4,588 | $13.05 | $59,891.75 |
DisclosureSEC source: 0001140361-24-047756 · form4.xml · nonDerivative · entry 1 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 392,395 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 20:26 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 3,989 | $18.50 | $73,812.46 |
DisclosureSEC source: 0001140361-24-037933 · form4.xml · nonDerivative · entry 1 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 396,983 F1 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| May 16, 2024 Filed May 20, 2024 20:26 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 4,046 | $23.35 | $94,474.10 |
DisclosureSEC source: 0001140361-24-026871 · form4.xml · nonDerivative · entry 6 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,972 F5 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| May 14, 2024 Filed May 20, 2024 20:26 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionRestricted Stock Units · Derivative | 5,533 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-026871 · form4.xml · derivative · entry 10 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,735 Underlying: Common Stock · 5,533 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. F2 · derivative.expiration_date: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| May 14, 2024 Filed May 20, 2024 20:26 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionRestricted Stock Units · Derivative | 3,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-026871 · form4.xml · derivative · entry 9 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,970 Underlying: Common Stock · 3,990 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents RSUs initially granted on February 14, 2022. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F1 · derivative.exercise_date: Represents RSUs initially granted on February 14, 2022. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. F1 · derivative.expiration_date: Represents RSUs initially granted on February 14, 2022. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| May 14, 2024 Filed May 20, 2024 20:26 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 5,553 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-026871 · form4.xml · nonDerivative · entry 2 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 301,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| May 14, 2024 Filed May 20, 2024 20:26 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 3,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-026871 · form4.xml · nonDerivative · entry 1 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 296,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents RSUs initially granted on February 14, 2022. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 01:54 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 98,183 | $0.00 Strike: $30.01 | $0.00 |
DisclosureSEC source: 0001140361-24-008889 · form4.xml · derivative · entry 5 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,183 Underlying: Common Stock · 98,183 shares Expires 2034-02-16 F6 · derivative.exercise_date: This option represents a right to purchase a total of 98,183 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 16, 2025, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 01:54 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantCommon Stock | 33,288 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-008889 · form4.xml · nonDerivative · entry 2 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,634 F1 · security: The shares beneficially owned by the reporting person are subject to a lock-up agreement dated September 12, 2023 (the "Lock-Up Agreement"). F4 · security: Represent RSUs that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on February 16, 2025, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 01:54 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 7,132 | $29.84 | $212,804.62 |
DisclosureSEC source: 0001140361-24-008889 · form4.xml · nonDerivative · entry 1 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,346 F1 · security: The shares beneficially owned by the reporting person are subject to a lock-up agreement dated September 12, 2023 (the "Lock-Up Agreement"). F2 · shares: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person. F3 · shares: The shares of common stock were sold by the Reporting Person pursuant to an exemption to the Lock-Up Agreement in order to pay tax withholding obligations in connection with the vesting of RSUs. Notwithstanding the sales reported on this Form 4, the securities beneficially owned by the reporting person remain subject to the terms of the Lock-Up Agreement. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionRestricted Stock Units · Derivative | 22,199 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-008358 · form4.xml · derivative · entry 5 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,268 Underlying: Common Stock · 22,199 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal annual installments over the following two years. F5 · derivative.expiration_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal annual installments over the following two years. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionRestricted Stock Units · Derivative | 3,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-008358 · form4.xml · derivative · entry 4 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,960 Underlying: Common Stock · 3,990 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal annual installments over the following two years. F4 · derivative.expiration_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal annual installments over the following two years. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 26,189 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-008358 · form4.xml · nonDerivative · entry 1 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. F1 · shares: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. Read SEC document |
| November 14, 2023 Filed Nov 17, 2023 00:17 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionRestricted Stock Units · Derivative | 3,989 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-053711 · form4.xml · derivative · entry 4 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,950 Underlying: Common Stock · 3,989 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal annual installments over the following two years. F4 · derivative.expiration_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal annual installments over the following two years. Read SEC document |
| November 14, 2023 Filed Nov 17, 2023 00:17 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 3,989 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-053711 · form4.xml · nonDerivative · entry 1 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,437 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. F1 · shares: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. Read SEC document |
| October 05, 2023 Filed Oct 10, 2023 20:11 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionRestricted Stock Units · Derivative | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-047589 · form4.xml · derivative · entry 4 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By Adaptive Technology LLC Disclosed balance after: 0 Underlying: Common Stock · 3,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: One-third (1/3) of such RSUs became fully vested and exercisable on October 5, 2021, with the remaining shares vesting in equal annual installments over the following two years. F4 · derivative.expiration_date: One-third (1/3) of such RSUs became fully vested and exercisable on October 5, 2021, with the remaining shares vesting in equal annual installments over the following two years. F2 · ownership.nature: The shares are held indirectly through Adaptive Technology, LLC, ("Adaptive Technology") a limited liability company that is owned and managed by the reporting person's husband. The restricted stock units were granted to Adaptive Technology, in connection with a Consulting Agreement for information technology services provided to the Company. Read SEC document |
| October 05, 2023 Filed Oct 10, 2023 20:11 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-047589 · form4.xml · nonDerivative · entry 1 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By Adaptive Technology LLC Disclosed balance after: 101,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. F1 · shares: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. F2 · ownership.nature: The shares are held indirectly through Adaptive Technology, LLC, ("Adaptive Technology") a limited liability company that is owned and managed by the reporting person's husband. The restricted stock units were granted to Adaptive Technology, in connection with a Consulting Agreement for information technology services provided to the Company. Read SEC document |
| August 17, 2023 Filed Aug 21, 2023 20:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 1,534 | $15.47 | $23,732.51 |
DisclosureSEC source: 0001140361-23-040695 · form4.xml · nonDerivative · entry 1 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,448 F1 · security: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person. F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person. Read SEC document |
| August 14, 2023 Filed Aug 15, 2023 20:16 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionRestricted Stock Units · Derivative | 3,989 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-039904 · form4.xml · derivative · entry 4 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,993 Underlying: Common Stock · 3,989 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. F4 · derivative.expiration_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| August 14, 2023 Filed Aug 15, 2023 20:16 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 3,989 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-039904 · form4.xml · nonDerivative · entry 1 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. F1 · shares: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 1,330 | $21.38 | $28,428.75 |
DisclosureSEC source: 0001140361-23-025743 · form4.xml · nonDerivative · entry 1 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,993 F1 · security: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person. F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person. Read SEC document |
| May 14, 2023 Filed May 16, 2023 23:57 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionRestricted Stock Units · Derivative | 3,989 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-025131 · form4.xml · derivative · entry 4 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,982 Underlying: Common Stock · 3,989 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. F4 · derivative.expiration_date: One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| May 14, 2023 Filed May 16, 2023 23:57 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 3,989 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-025131 · form4.xml · nonDerivative · entry 1 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. F1 · shares: Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:45 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantRestricted Stock Units · Derivative | 66,467 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-007483 · form4.xml · derivative · entry 2 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,467 Underlying: Common Stock · 66,467 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. F3 · derivative.expiration_date: One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:45 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 199,194 | $0.00 Strike: $20.04 | $0.00 |
DisclosureSEC source: 0001140361-23-007483 · form4.xml · derivative · entry 1 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,194 Underlying: Common Stock · 199,194 shares Expires 2033-02-13 F1 · derivative.exercise_date: This option represents a right to purchase a total of 199,194 shares of the Issuer's common stock, one-third (1/3) of which will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2023 Filed Feb 23, 2023 00:25 UTC Amendment | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionRestricted Stock Units · Derivative | 15,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-008100 · form4.xml · derivative · entry 6 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,917 Underlying: Common Stock · 15,720 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The original Form 4, filed on February 16, 2023, is being amended by this amendment to include the vesting of restricted stock units that took place on February 14, 2023. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F7 · derivative.exercise_date: One-third (1/3) of such restricted stock units became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. F7 · derivative.expiration_date: One-third (1/3) of such restricted stock units became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2023 Filed Feb 23, 2023 00:25 UTC Amendment | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantRestricted Stock Units · Derivative | 66,467 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-008100 · form4.xml · derivative · entry 5 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,467 Underlying: Common Stock · 66,467 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. F6 · derivative.expiration_date: One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2023 Filed Feb 23, 2023 00:25 UTC Amendment | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 199,194 | $0.00 Strike: $20.04 | $0.00 |
DisclosureSEC source: 0001140361-23-008100 · form4.xml · derivative · entry 4 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,194 Underlying: Common Stock · 199,194 shares Expires 2033-02-13 F4 · derivative.exercise_date: This option represents a right to purchase a total of 199,194 shares of the Issuer's common stock, one-third (1/3) of which will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2023 Filed Feb 23, 2023 00:25 UTC Amendment | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 15,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-008100 · form4.xml · nonDerivative · entry 1 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,566 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The original Form 4, filed on February 16, 2023, is being amended by this amendment to include the vesting of restricted stock units that took place on February 14, 2023. F2 · shares: Represents shares of Common Stock received upon vesting of a restricted stock unit award. Read SEC document |
| February 14, 2023 Filed May 20, 2024 20:26 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | OtherRestricted Stock Units · Derivative | 38,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-026871 · form4.xml · derivative · entry 13 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,735 shares Expires not disclosed F2 · security: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · kind: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F2 · derivative.exercise_date: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. F2 · derivative.expiration_date: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2023 Filed May 20, 2024 20:26 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | OtherCommon Stock | 38,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-026871 · form4.xml · nonDerivative · entry 5 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 405,018 F2 · security: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. F3 · security: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F3 · kind: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 21:31 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantRestricted Stock Units · Derivative | 52,489 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-029892 · form4.xml · derivative · entry 1 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,489 Underlying: Common Stock · 52,489 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units will become fully vested on August 12, 2025. F2 · derivative.expiration_date: The restricted stock units will become fully vested on August 12, 2025. Read SEC document |
| August 12, 2022 Filed May 20, 2024 20:26 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | OtherRestricted Stock Units · Derivative | 52,489 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-026871 · form4.xml · derivative · entry 12 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,489 shares Expires not disclosed F4 · security: Represents RSUs initially granted on August 12, 2022, which vest in full on August 12, 2025. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · kind: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F4 · derivative.exercise_date: Represents RSUs initially granted on August 12, 2022, which vest in full on August 12, 2025. F4 · derivative.expiration_date: Represents RSUs initially granted on August 12, 2022, which vest in full on August 12, 2025. Read SEC document |
| August 12, 2022 Filed May 20, 2024 20:26 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | OtherCommon Stock | 52,489 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-026871 · form4.xml · nonDerivative · entry 4 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 366,283 F3 · security: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F4 · security: Represents RSUs initially granted on August 12, 2022, which vest in full on August 12, 2025. F3 · kind: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 02:03 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantRestricted Stock Units · Derivative | 47,637 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-005826 · form4.xml · derivative · entry 2 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,637 Underlying: Common Stock · 47,637 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. F3 · derivative.expiration_date: One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 02:03 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 148,518 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001140361-22-005826 · form4.xml · derivative · entry 1 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,518 Underlying: Common Stock · 148,518 shares Expires 2032-02-13 F1 · derivative.exercise_date: This option represents a right to purchase a total of 148,518 shares of the Issuer's common stock, one-third (1/3) of which will become fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2022 Filed May 20, 2024 20:26 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | OtherRestricted Stock Units · Derivative | 11,970 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-026871 · form4.xml · derivative · entry 11 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,970 shares Expires not disclosed F1 · security: Represents RSUs initially granted on February 14, 2022. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · kind: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F1 · derivative.exercise_date: Represents RSUs initially granted on February 14, 2022. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. F1 · derivative.expiration_date: Represents RSUs initially granted on February 14, 2022. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| February 14, 2022 Filed May 20, 2024 20:26 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | OtherCommon Stock | 11,970 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-026871 · form4.xml · nonDerivative · entry 3 Patel Kinnari · CIK 0001725929 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 313,794 F1 · security: Represents RSUs initially granted on February 14, 2022. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years. F3 · security: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. F3 · kind: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs. Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 22:17 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionStock Option (Right to Buy) · Derivative | 38,093 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001140361-21-010348 · form4.xml · derivative · entry 6 Patel Kinnari · CIK 0001725929 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Sock · 38,093 shares Expires 2027-04-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 22:17 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionStock Option (Right to Buy) · Derivative | 55,869 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0001140361-21-010348 · form4.xml · derivative · entry 5 Patel Kinnari · CIK 0001725929 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Sock · 55,869 shares Expires 2026-04-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 22:17 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 38,093 | $1.69 | $64,377.17 |
DisclosureSEC source: 0001140361-21-010348 · form4.xml · nonDerivative · entry 2 Patel Kinnari · CIK 0001725929 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 22:17 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 55,869 | $1.21 | $67,601.49 |
DisclosureSEC source: 0001140361-21-010348 · form4.xml · nonDerivative · entry 1 Patel Kinnari · CIK 0001725929 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2021 Filed Feb 9, 2021 01:48 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $62.32 | $0.00 |
DisclosureSEC source: 0001140361-21-003787 · form4.xml · derivative · entry 1 Patel Kinnari · CIK 0001725929 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Sock · 120,000 shares Expires 2031-02-03 F1 · derivative.exercise_date: The option represents a right to purchase a total of 120,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 4, 2022, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 21:50 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 5,427 | $57.17 | $310,237.71 |
DisclosureSEC source: 0001140361-20-029917 · form4.xml · nonDerivative · entry 2 Patel Kinnari · CIK 0001725929 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,977 F2 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan dated 10/23/2020 in multiple trades at prices ranging from $56.903 to $57.49. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.